Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    somapacitan-beco

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novo Nordisk`s Biologics Sogroya Receive Suppl Approval in US
    Novo Nordisk`s Biologics Sogroya Receive Suppl Approval in US

    09 Jul 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761156

    FDA
    09 Jul 2025
    Share Share
    Novo Nordisk: Sogroya effective in children with growth disorders
    Novo Nordisk: Sogroya effective in children with growth disorders

    13 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/12/3078801/0/en/Novo-Nordisk-A-S-Once-weekly-Sogroya-somapacitan-is-an-efficacious-and-well-tolerated-long-acting-growth-hormone-in-children-with-growth-disorders-results-from-REAL8-phase-3-basket.html

    GLOBENEWSWIRE
    13 May 2025
    Share Share
    Novo Nordisk’s once-weekly Sogroya gets CHMP recommendation
    Novo Nordisk’s once-weekly Sogroya gets CHMP recommendation

    29 May 2023

    // PHARMABIZ

    http://pharmabiz.com/NewsDetails.aspx?aid=159411&sid=2

    PHARMABIZ
    29 May 2023
    Share Share
    Novo Nordisk: Once-weekly Sogroya® (somapacitan) receives CHMP positive opinion
    Novo Nordisk: Once-weekly Sogroya® (somapacitan) receives CHMP positive opinion

    26 May 2023

    // PRESS RELEASE

    https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166112

    PRESS RELEASE
    26 May 2023
    Share Share
    Novo Nordisk: Once-weekly Sogroya receives CHMP positive opinion
    Novo Nordisk: Once-weekly Sogroya receives CHMP positive opinion

    26 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/26/2676885/0/en/Novo-Nordisk-A-S-Once-weekly-Sogroya-somapacitan-receives-CHMP-positive-opinion-for-expanded-use-in-children-and-adolescents-with-growth-hormone-deficiency.html

    GLOBENEWSWIRE
    26 May 2023
    Share Share
    Sogroya data show potential as once-weekly treatment in GHD
    Sogroya data show potential as once-weekly treatment in GHD

    12 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/12/2460802/0/en/Novo-Nordisk-A-S-Sogroya-data-show-potential-as-once-weekly-treatment-in-children-living-with-growth-hormone-deficiency.html

    GLOBENEWSWIRE
    12 Jun 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.